BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML
Science Translational Medicine · 11.09.2024 · 16 (764)
DOI: 10.1126/scitranslmed.adp0004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 11.09.2024. Verfasst von Bijender Kumar und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Epigenesis, Genetic, Basic-Leucine Zipper Transcription Factors, Killer Cells, Natural. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Myelodysplastic syndrome and acute myeloid leukemia (AML) belong to a continuous disease spectrum of myeloid malignancies with poor prognosis in the relapsed/refractory setting necessitating novel therapies. Natural killer (NK) cells from patients with myeloid malignancies display global dysfunction with impaired killing capacity, altered metabolism, and an exhausted phenotype at the single-cell transcriptomic and proteomic levels. In this study, we identified that this dysfunction was mediated through a cross-talk between NK cells and myeloid blasts necessitating cell-cell contact. NK cell dysfunction could be prevented by targeting the αvβ-integrin/TGF-β/SMAD pathway but, once established, was persistent because of profound epigenetic reprogramming. We identified BATF as a core transcription factor and the main mediator of this NK cell dysfunction in AML. Mechanistically, we found that BATF was directly regulated and induced by SMAD2/3 and, in turn, bound to key genes related to NK cell exhaustion, such as HAVCR2 , LAG3 , TIGIT , and CTLA4 . BATF deletion enhanced NK cell function against AML in vitro and in vivo. Collectively, our findings reveal a previously unidentified mechanism of NK immune evasion in AML manifested by epigenetic rewiring and inactivation of NK cells by myeloid blasts. This work highlights the importance of using healthy allogeneic NK cells as an adoptive cell therapy to treat patients with myeloid malignancies combined with strategies aimed at preventing the dysfunction by targeting the TGF-β pathway or BATF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Department of Stem Cell Transplantation and Hemotherapy/Cellular Therapy, Hospital Israelita Albert Einstein, Sao Paulo 05652-900, Brazil.
- Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Bijender Kumar, Anand Singh, Rafet Basar, Nadima Uprety, Ye Li, Huihui Fan, Ana Karen Nunez Cortes, Mecit Kaplan, Sunil Acharya, Anna C Xu, Manrong Wu, Dexing Fang, Silvia Tiberti, Paul Lin, Hind Rafei, Maliha Nuzhat Munir, Madison Moore, Mayra Shanley, Alexander Biederstädt, Susmita Ghosh, Kiran Kundu, Francia Reyes-Silva, April L Gilbert, Merve Dede, Vakul Mohanty, Jinzhuang Dou, Gary M Deyter, Abhinav K Jain, Juan Jose Rodriguez-Sevilla, Guillermo Garcia-Manero, Elizabeth J Shpall, Ken Chen, Hussein A Abbas, Kunal Rai, Katayoun Rezvani, May Daher
Förderung
- NCI NIH HHS
Zitieren
APA
Kumar, B., Singh, A., Basar, R., Uprety, N., Li, Y., Fan, H., Cortes, A. K. N., Kaplan, M., Acharya, S., Shaim, H., Xu, A. C., Wu, M., Ensley, E., Fang, D., Banerjee, P. P., Garcia, L. M., Tiberti, S., Lin, P., Rafei, H., …, & Daher, M. (2024). BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Science Translational Medicine, 16(764). https://doi.org/10.1126/scitranslmed.adp0004
Vancouver
Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, et al. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Science Translational Medicine. 2024;16(764). doi:10.1126/scitranslmed.adp0004
BibTeX
@article{Kumar2024,
author = {Kumar, Bijender and Singh, Anand and Basar, Rafet and Uprety, Nadima and Li, Ye and Fan, Huihui and Cortes, Ana Karen Nunez and Kaplan, Mecit and Acharya, Sunil and Shaim, Hila and Xu, Anna C and Wu, Manrong and Ensley, Emily and Fang, Dexing and Banerjee, Pinaki P and Garcia, Luciana Melo and Tiberti, Silvia and Lin, Paul and Rafei, Hind and Munir, Maliha Nuzhat and Moore, Madison and Shanley, Mayra and Mendt, Mayela and Kerbauy, Lucila N and Liu, Bin and Biederstädt, Alexander and Gokdemir, Elif and Ghosh, Susmita and Kundu, Kiran and Reyes-Silva, Francia and Jiang, Xin Ru and Wan, Xinhai and Gilbert, April L and Dede, Merve and Mohanty, Vakul and Dou, Jinzhuang and Zhang, Patrick and Liu, Enli and Muniz-Feliciano, Luis and Deyter, Gary M and Jain, Abhinav K and Rodriguez-Sevilla, Juan Jose and Colla, Simona and Garcia-Manero, Guillermo and Shpall, Elizabeth J and Chen, Ken and Abbas, Hussein A and Rai, Kunal and Rezvani, Katayoun and Daher, May},
title = {BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {764},
doi = {10.1126/scitranslmed.adp0004}
}
EUVIMED